<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

9 min read

Europe: New Routines in Greetings and in Wound Management

By Anikó Szekér on 12/21/20 10:21 AM

SmartTRAK examines the Top 5 countries in Europe during the time of COVID-19 and estimates how the Advanced Wound Dressing Market will be impacted in 2020 and 2021.

Using an elbow bump instead of a handshake or hug is not the only new routine people have learned during the pandemic. As winter arrives with an expected surge in COVID-19, healthcare systems and services in Europe are building on lessons learned from the spring outbreak to help shape the way health services will be delivered in the coming months.

Amid this pandemic, several factors are affecting growth in the European Advanced Dressings Market, which is projected to reach ~$2.07B (€1.85B) by 2024 according to SmartTRAK estimates. In this article, SmartTRAK reviews how the COVID-19 pandemic has evolved in Europe and how it is impacting the market for Advanced Dressings in France, Germany, the UK, Spain and Italy.

Continue Reading
2 min read

Gain vs Loss: Q320 Infection Prevention: US Vascular Access Adjunct Market

By Susan Paquette on 12/18/20 10:44 AM

Q3 makes a recovery from Q220 losses but gains remain below pre-COVID levels

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention-Vascular Access Adjunct Products market was down -1.8% YoY. Leading manufacturers in this segment hit hard in Q220 by COVID-19 restrictions and elective procedure cancellations reported positive growth over Q2, but are still not at pre-COVID-19 levels.

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Infection Prevention: US Vascular Access Adjunct Market Recap* are:

Topics: Wound Care
Continue Reading
2 min read

Navigating the New Norm: Q320 Orthbio Market Recap

By Kim French on 12/17/20 10:10 AM

Orthopedics market stages a third-quarter rally while navigating a new norm.

As the US healthcare system adjusts to the “new” norm brought on by the COVID-19 pandemic, the US Orthobiologics market rallied in Q320, ending the quarter up +2.3% YoY. 

Among the many topics, including company revenues, shares, charts and expert analysis, covered in the comprehensive Q320 Orthobio Market Recap* are:
Continue Reading
2 min read

Bouncing Back: Q320 Advanced Wound Care (AWC) Market Recap

By Susan Paquette on 12/16/20 9:30 AM

In Q320, Advanced Wound Care bounced back to almost normal levels amidst the COVID-19 pandemic with patients returning for chronic wound treatment.

For Q320, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics increased slightly YoY.

3M* remained the WW market leader, up +1.5% YoY, driven by tentative signs of improvement in elective procedures. WW Advanced Dressings returned to positive growth, with mixed performance among leading players. US Skin/Dermal Substitute (CTP) revenue rebounded over Q319, driven by a whopping performance by Organogenesis, while WW NPWT was down slightly YoY, with single-use down and traditional devices flat.

Among the many topics covered in the comprehensive Q320 Advanced Wound Market Recap* are:

Topics: Wound Care
Continue Reading
2 min read

Fanning the Flames of Growth: Q320 Extremities Market Recap

By Lisa Mahan on 12/14/20 10:45 AM

Return of elective procedures in Q320 fanned the flames of Extremities growth.

The return of elective procedures, along with the opening up of the US, fanned the flames of growth in the US with the Extremities Market returning to pre-COVID growth levels in Q320. Strength in both the Upper Extremities and Foot & Ankle Market fueled the fire with US Extremities heating up with +6.6% growth, according to SmartTRAK Financial Dashboard. The US Shoulder Replacement market segment brought the heat in US Upper Extremities which grew +6.3%, while Foot & Ankle Fixation and Ankle Replacement were also up, adding fuel to the fire in the Foot & Ankle market segment.
Topics: Orthopedics
Continue Reading
12 min read

Orchid: The Evolution of Contract Manufacturing

By Lisa Mahan on 12/11/20 2:38 PM

Orchid Orthopedic Solutions CEO Nate Folkert discusses Orchid and the changing landscape of contract manufacturing

With locations around the globe, Orchid Orthopedic Solutions has partnered with established medical device companies, start-ups and surgeon entrepreneurs. The Company, which was established in 2005, has evolved to include facilities at 13 locations worldwide offering a range of services from contract design and development through finished goods manufacturing and packaging.

Orchid CEO Nate Folkert discusses his recent transition from the device company side of the Orthopedic business to the supply side, the evolving nature of the supply side business and the changes that have come about as a result of the COVID-19 pandemic. Click on the following video to listen to SmartTRAK’s interview with Folkert recorded live via Zoom (15:09 min). A complete transcript of the interview, with a link to download it, is also provided below.

Topics: Orthopedics
Continue Reading
2 min read

COVID Casting Shadows of Doubt on a Rebound: Q320 Spine Market Recap

By Julianne Burns on 12/11/20 11:40 AM

Rising COVID cases in the US casting shadows of doubt on ongoing rebound for the Spine market. 

Quarterly results hint at a sustained rebound for the Spine market even as the US faces a surge of COVID cases. WW Spine Hardware revenues were up as surgeons worked through a backlog of patients postponed due to COVID-19. The US Spinal Fusion Market saw a +3.6% uptick in Q320, with the US Disc Replacement market, VCF and Dynamic Devices all showing growth, according to SmartTRAK Financial Dashboard.

In an October Needham Spine & Robotics Expert Call, Spine surgeon Dr. Peter Whang noted that he and his peers were operating at full capacity at the time with a large backlog of patients to work through. In order to catch up on cases, accommodations are being made with extended clinic hours and elective cases scheduled on weekends. Dr. Whang affirms that COVID has accelerated the shift of spine procedures to an ASC setting and notes that ASC cases recovered faster and will be more resistant to any restrictions due to future COVID spikes.

Among the many topics covered in the comprehensive Q320 Spine Market Recap* are:

Continue Reading
3 min read

Magstim: Opportunities in Transcranial Magnetic Stimulation: An Interview with Lothar Krinke

By Anne Staylor on 12/8/20 9:09 AM

Magstim CEO Lothar Krinke, PhD discusses Magstim and opportunities in transcranial magnetic stimulation in an interview with SmartTRAK

As a pioneer in transcranial magnetic stimulation (TMS), Magstim has been a leading supplier of transcranial magnetic stimulators for the last 30 years. Although TMS was first primarily used for research applications, it is now widely used in the clinical setting as a non-invasive therapy to treat major depressive disorder in patients who have failed medication therapy or other treatments. Magstim estimates approximately 50,000+ patients per year in the US receive TMS therapy for depression, a fraction of the five-to-six million patients who currently suffer from medication-resistant depression. 

The combined worldwide market for TMS, including the clinical and research market, is estimated at ~$200 million a year, but it is potentially a multi-billion dollar market according to Magstim CEO Lothar Krinke, PhD. To find out more about TMS and Magstim, including its recent acquisition of Electrical Geodesics (EGI) and its high-density EEG from Royal Philips, click on the following video to listen to SmartTRAK’s interview with Dr. Krinke, recorded live via Uberconference (31:05 min). To download a complete transcript of the interview, just click the link below.

Continue Reading
2 min read

A Journey Back to Normalcy: Q320 Hemostats and Sealants Market Recap

By Doug Devens on 12/7/20 9:58 AM

The US market for Hemostats and Sealants began the journey back to normalcy, slipping -0.2% YoY in Q320, as elective surgeries began to be performed again. Hemostats led the charge with Sealants not far behind.

As the US healthcare system begins to manage COVID-19 and elective procedures return toward pre-COVID-19 levels, the US Hemostats and Sealants market rebounded with a drop of only -0.2% YoY in Q320 according to SmartTRAK Financial Dashboard. Most manufacturers still experienced declines in Q320, but far narrower than the losses of Q220. Ethicon* managed a +4.5% gain in Q320 while the other manufacturers essentially treaded water with respect to Q319.

Among the many topics covered in the comprehensive Q320 US Hemostats and Sealants Market Recap* are:

Topics: Wound Care
Continue Reading
2 min read

Back on Track: Q320 Total Joints Market Recap

By Lisa Mahan on 12/4/20 11:39 AM

After the pandemic derailed the market in Q220, Total Joints was getting back on track in Q3

The COVID-19 pandemic derailed the Total Joints Market in Q220 with stay-at-home orders and elective procedure shutdowns. But the market seemed back on track in Q320 as elective procedural volumes increased and revenues neared pre-COVID levels. With the market chugging along, the US Total Joints Market experienced positive growth during the quarter of +2.5%, according to SmartTRAK Financial Dashboard. The Hip Market was able to quickly gain steam due to the less elective nature of the procedure compared to Knees. In Q320, the US Hip Market grew +7.6% compared to the US Knee Market which was nearing pre-COVID levels at -1.1%.

Among the many topics covered in the comprehensive Q320 Total Joints Market Recap* are:

Continue Reading

    Recent Articles